ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Infection-related Rheumatic Disease Poster

Date: Saturday, November 7, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM
Abstract Number: 0630
“No Benefit from a Strict Immobilization in Vertebral Osteomyelitis” Vertebral Immobilization and Neurological Complication in Acute Pyogenic Vertebral Osteomyelitis: SPONDIMMO, a Prospective Cohort of 250 Patients
9:00AM-11:00AM
Abstract Number: 0624
Association of Regional Body Composition and Physical Function Using the Short Physical Performance Battery Among Peruvian Women with HIV
9:00AM-11:00AM
Abstract Number: 0644
Characterizations of Cytokine Storm Associated with COVID19
9:00AM-11:00AM
Abstract Number: 0637
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
9:00AM-11:00AM
Abstract Number: 0631
Clinical Manifestations and Outcomes in DMARD-Naïve Patients with Chronic Chikungunya Arthritis
9:00AM-11:00AM
Abstract Number: 0641
Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?
9:00AM-11:00AM
Abstract Number: 0627
Complications of COVID-19 Infection in Patients with Rheumatic Disease: A Case Series
9:00AM-11:00AM
Abstract Number: 0629
COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study
9:00AM-11:00AM
Abstract Number: 0640
Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence
9:00AM-11:00AM
Abstract Number: 0642
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
9:00AM-11:00AM
Abstract Number: 0623
Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort
9:00AM-11:00AM
Abstract Number: 0626
Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients
9:00AM-11:00AM
Abstract Number: 0621
Effectiveness of Screening in Patients with Rheumatic Disease Before Commencing Biologic Therapy and Risk of Active Tuberculosis
9:00AM-11:00AM
Abstract Number: 0628
Factors Associated with Knee Osteoarthritis in an Outpatient HIV-1 Clinic over a 26 Year Interval
9:00AM-11:00AM
Abstract Number: 0635
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 0639
Immunological Abnormalities in a SARS-CoV-2-Cytokine Release Syndrome Rheumatology Cohort
9:00AM-11:00AM
Abstract Number: 0622
Infection-induced MPO-ANCA Associated Vasculitis: A Systematic Review of Published Case Reports
9:00AM-11:00AM
Abstract Number: 0634
Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 0625
Machine Learning Model to Predict Culture Positivity in Suspected Septic Arthritis
9:00AM-11:00AM
Abstract Number: 0645
Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis
9:00AM-11:00AM
Abstract Number: 0636
Rheumatology Patient Experience and Trends During the SARS-COV-2 Pandemic
9:00AM-11:00AM
Abstract Number: 0638
Serological Evidence of SARS-CoV-2 in Symptomatic Patients Under Biological Treatment in a Rheumatology Service
9:00AM-11:00AM
Abstract Number: 0632
Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases
9:00AM-11:00AM
Abstract Number: 0643
Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
9:00AM-11:00AM
Abstract Number: 0633
Vitamin D Serum Status in a Cohort of COVID-19 Patients

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology